New Advances in Typhoid Fever Vaccination Strategies

  • Zulfiqar A. BhuttaEmail author
  • M. Imran Khan
  • Sajid Bashir Soofi
  • R. Leon Ochiai
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 697)


Salmonella belong to the group of Enterobacteriaceae that are aerobic, gram-negative rods and approximately 1–3 μm × 0.5 μm in size [1, 2]. Currently there are approximately 2,400 pathogenic species of salmonella. Salmonella was first identified in 1880 by Eberth from the mesenteric nodes and spleen of a patient dying from typhoid fever [3, 4].


Typhoid Fever Case Fatality Rate Bone Marrow Culture Food Handler National Immunization Program 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med. 2002 Nov 28;347(22):1770–82.Google Scholar
  2. 2.
    Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet. 2005 Aug 27–Sep 2;366(9487):749–62.Google Scholar
  3. 3.
    Eberth. Oranismen in den Organen bei. Typhus abdominalis. Virchows Arch Path Anal. 1880;81:16.Google Scholar
  4. 4.
    Skerman VBD, McGowan V, Sneath PHA. Approved lists of bacterial names. Int J Syst Bacteriol. 1980;30:195.CrossRefGoogle Scholar
  5. 5.
    Gaffky. Aetiologie des Abdominaltyphus: Mittheilungen aus dem kaiserlichen Gesundheitsante. Feischsgesundheitsamt. 1884;48.Google Scholar
  6. 6.
    Edwards PR, Ewing WH. Identification of Enterobacteriaceae. Minneapolis, MN: Bugess Publishing Co; 1972.Google Scholar
  7. 7.
    Felix A, Pitt RM. A new antigen of B. typhosus. Lancet. 1934 July 28;224(5787):6.Google Scholar
  8. 8.
    Wong KH, Feeley JC, Northrup RS, Forlines ME. Vi antigen from Salmonella typhosa and immunity against typhoid fever. I. Isolation and immunologic properties in animals. Infect Immun. 1974 Feb;9(2):348–53.Google Scholar
  9. 9.
    Mehta G, Arya SC. Capsular Vi polysaccharide antigen in Salmonella enterica serovar typhi isolates. J Clin Microbiol. 2002 Mar;40(3):1127–8.Google Scholar
  10. 10.
    Robbins JD, Robbins JB. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis. 1984 Sep;150(3):436–49.Google Scholar
  11. 11.
    Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ. 2004 May;82(5):346–53.Google Scholar
  12. 12.
    Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull World Health Organ. 1994;72(6):957–71.Google Scholar
  13. 13.
    Crump JA, Ram PK, Gupta SK, Miller MA, Mintz ED. Part I. Analysis of data gaps pertaining to Salmonella enterica serotype typhi infections in low and medium human development index countries, 1984–2005. Epidemiol Infect. 2008 Apr;136(4):436–48.Google Scholar
  14. 14.
    Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ. 2008 Apr;86(4):260–8.Google Scholar
  15. 15.
    DeRoeck D, Jodar L, Clemens J. Putting typhoid vaccination on the global health agenda. N Engl J Med. 2007 Sep 13;357(11):1069–71.Google Scholar
  16. 16.
    Brooks WA, Hossain A, Goswami D, Nahar K, Alam K, Ahmed N et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis. 2005 Feb;11(2):326–9.Google Scholar
  17. 17.
    Sinha A, Sazawal S, Kumar R, Sood S, Reddaiah VP, Singh B et al. Typhoid fever in children aged less than 5 years. Lancet. 1999 Aug 28;354(9180):734–37.Google Scholar
  18. 18.
    Siddiqui FJ, Rabbani F, Hasan R, Nizami SQ, Bhutta ZA. Typhoid fever in children: some epidemiological considerations from Karachi, Pakistan. Int J Infect Dis. 2006 May;10(3):215–22.Google Scholar
  19. 19.
    Saha SK, Baqui AH, Hanif M, Darmstadt GL, Ruhulamin M, Nagatake T et al. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr Infect Dis J. 2001 May;20(5):521–4.Google Scholar
  20. 20.
    Vollaard AM, Ali S, van Asten HA, Widjaja S, Visser LG, Surjadi C et al. Risk factors for typhoid and paratyphoid fever in Jakarta, Indonesia. JAMA. 2004 June 2;291(21):2607–15.Google Scholar
  21. 21.
    Edelman R, Levine MM. Summary of an international workshop on typhoid fever. Rev Infect Dis. 1986 May–Jun;8(3):329–49.Google Scholar
  22. 22.
    Maskey AP, Basnyat B, Thwaites GE, Campbell JI, Farrar JJ, Zimmerman MD. Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. Trans R Soc Trop Med Hyg. 2008 Jan;102(1):91–5.Google Scholar
  23. 23.
    Uneke CJ. Concurrent malaria and typhoid fever in the tropics: the diagnostic challenges and public health implications. J Vector Borne Dis. 2008 Jun;45(2):133–42.Google Scholar
  24. 24.
    Butler T, Islam A, Kabir I, Jones PK. Patterns of morbidity and mortality in typhoid fever dependent on age and gender: review of 552 hospitalized patients with diarrhea. Rev Infect Dis. 1991 Jan–Feb;13(1):85–90.Google Scholar
  25. 25.
    Chatterjee H, Jagdish S, Pai D, Satish N, Jayadev D, Reddy PS. Changing trends in outcome of typhoid ileal perforations over three decades in Pondicherry. Trop Gastroenterol. 2001 July–Sep;22(3):155–8.Google Scholar
  26. 26.
    Mweu E, English M. Typhoid fever in children in Africa. Trop Med Int Health. 2008 Apr;13(4):532–40.Google Scholar
  27. 27.
    Thaver D, Zaidi AK, Critchley JA, Azmatullah A, Madni SA, Bhutta ZA. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev. 2008;4:CD004530.PubMedGoogle Scholar
  28. 28.
    Akpede GO, Akenzua GI. Management of children with prolonged fever of unknown origin and difficulties in the management of fever of unknown origin in children in developing countries. Paediatr Drugs. 2001;3(4):247–62.CrossRefPubMedGoogle Scholar
  29. 29.
    Yang J. Enteric Fever in South China: Guangxi Province. J Infect Dev Ctries. 2008;2(4):6.Google Scholar
  30. 30.
    Gil R, Alvarez JL, Gomez C, Alvaro A, Gil A. Epidemiology of typhoid and paratyphoid fever hospitalizations in Spain (1997-2005). Hum Vaccin. 2009 June;5(6):420–4.Google Scholar
  31. 31.
    Shukla S, Patel B, Chitnis DS. 100 years of Widal test & its reappraisal in an endemic area. Indian J Med Res. 1997 Feb;105:53–7.Google Scholar
  32. 32.
    Vallenas C, Hernandez H, Kay B, Black R, Gotuzzo E. Efficacy of bone marrow, blood, stool and duodenal contents cultures for bacteriologic confirmation of typhoid fever in children. Pediatr Infect Dis. 1985 Sep–Oct;4(5):496–8.Google Scholar
  33. 33.
    Bhutta ZA, Naqvi SH, Razzaq RA, Farooqui BJ. Multidrug-resistant typhoid in children: presentation and clinical features. Rev Infect Dis. 1991 Sep–Oct;13(5):832–6.Google Scholar
  34. 34.
    Naheed A, Ram PK, Brooks WA, Mintz ED, Hossain MA, Parsons MM et al. Clinical value of Tubex and Typhidot rapid diagnostic tests for typhoid fever in an urban community clinic in Bangladesh. Diagn Microbiol Infect Dis. 2008 Aug;61(4):381–6.Google Scholar
  35. 35.
    Chang JE, Hernandez H, Yi A, Chea E, Chaparro E, Matos E et al. [Hemoculture and bone marrow culture in children with typhoid fever]. Bol Med Hosp Infant Mex. 1982 Sep;39(9):614–16.Google Scholar
  36. 36.
    Whitaker JA, Franco-Paredes C, del Rio C, Edupuganti S. Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas. J Travel Med. 2009 Jan–Feb;16(1):46–52.Google Scholar
  37. 37.
    Tarr PE, Kuppens L, Jones TC, Ivanoff B, Aparin PG, Heymann DL. Considerations regarding mass vaccination against typhoid fever as an adjunct to sanitation and public health measures: potential use in an epidemic in Tajikistan. Am J Trop Med Hyg. 1999 Jul;61(1):163–70.Google Scholar
  38. 38.
    Levine MM, Lepage P. Prevention of typhoid fever. Adv Exp Med Biol. 2005;568:161–73.CrossRefPubMedGoogle Scholar
  39. 39.
    Barreto ML, Genser B, Strina A, Teixeira MG, Assis AM, Rego RF et al. Effect of city-wide sanitation programme on reduction in rate of childhood diarrhoea in northeast Brazil: assessment by two cohort studies. Lancet. 2007 Nov 10;370(9599):1622–8.Google Scholar
  40. 40.
    Stanton BF, Clemens JD. An educational intervention for altering water-sanitation behaviors to reduce childhood diarrhea in urban Bangladesh. II. A randomized trial to assess the impact of the intervention on hygienic behaviors and rates of diarrhea. Am J Epidemiol. 1987 Feb;125(2):292–301.Google Scholar
  41. 41.
    Luby SP, Agboatwalla M, Feikin DR, Painter J, Billhimer W, Altaf A et al. Effect of handwashing on child health: a randomised controlled trial. Lancet. 2005 Jul 16–22;366(9481):225–33.Google Scholar
  42. 42.
    Fewtrell L, Kaufmann RB, Kay D, Enanoria W, Haller L, Colford JM Jr. Water, sanitation, and hygiene interventions to reduce diarrhoea in less developed countries: a systematic review and meta-analysis. Lancet Infect Dis. 2005 Jan;5(1):42–52.Google Scholar
  43. 43.
    Guzman CA, Borsutzky S, Griot-Wenk M, Metcalfe IC, Pearman J, Collioud A et al. Vaccines against typhoid fever. Vaccine. 2006 May 1;24(18):3804–11.Google Scholar
  44. 44.
    Griffin GE. Typhoid fever and childhood vaccine strategies. Lancet. 1999 Aug 28;354(9180):698–9.Google Scholar
  45. 45.
    Whittington D, Sur D, Cook J, Chatterjee S, Maskery B, Lahiri M et al. Rethinking cholera and typhoid vaccination policies for the poor: private demand in Kolkata, India. World Dev. 2009 Feb;37(2):399–409.Google Scholar
  46. 46.
    Do GC, Whittington D, Le TK, Utomo N, Nguyen TH, Poulos C et al. Household demand for typhoid fever vaccines in Hue, Vietnam. Health Policy Plan. 2006 May;21(3):241–55.Google Scholar
  47. 47.
    DeRoeck D, Clemens JD, Nyamete A, Mahoney RT. Policymakers’ views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine. 2005 Apr 15;23(21):2762–74.Google Scholar
  48. 48.
    Hoffman SL, Punjabi NH, Kumala S, Moechtar MA, Pulungsih SP, Rivai AR et al. Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med. 1984 Jan 12;310(2):82–8.Google Scholar
  49. 49.
    Gupta B, Kumar R, Khurana S. Multi drug resistant Salmonella typhi in Ludhiana (Punjab). Indian J Pathol Microbiol. 1993 Jan;36(1):5–7.Google Scholar
  50. 50.
    Mirza SH, Beeching NJ, Hart CA. Multi-drug resistant typhoid: a global problem. J Med Microbiol. 1996 May;44(5):317–19.Google Scholar
  51. 51.
    Kato Y, Fukayama M, Adachi T, Imamura A, Tsunoda T, Takayama N et al. Multidrug-resistant typhoid fever outbreak in travelers returning from Bangladesh. Emerg Infect Dis. 2007 Dec;13(12):1954–5.Google Scholar
  52. 52.
    Coovadia YM, Gathiram V, Bhamjee A, Garratt RM, Mlisana K, Pillay N et al. An outbreak of multiresistant Salmonella typhi in South Africa. Q J Med. 1992 Feb;82(298):91–100.Google Scholar
  53. 53.
    Woodward TE, Smadel JE et al. Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever. Ann Intern Med. 1948 Jul;29(1):131–4.Google Scholar
  54. 54.
    Olarte J, Galindo E. Salmonella typhi resistant to chloramphenicol, ampicillin, and other antimicrobial agents: strains isolated during an extensive typhoid fever epidemic in Mexico. Antimicrob Agents Chemother. 1973 Dec;4(6):597–601.Google Scholar
  55. 55.
    Bahl R, Sinha A, Poulos C, Whittington D, Sazawal S, Kumar R et al. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy. J Health Popul Nutr. 2004 Sep;22(3):304–10.Google Scholar
  56. 56.
    Wright AE, Leishman W. Remarks on the results which have been obtained by the antityphoid inoculations and on the methods which have been employed in the preparation of the vaccine. Br Med J. 1900;1:8.Google Scholar
  57. 57.
    Hawley PR, Simmons JS. The effectiveness of vaccines used for the prevention of typhoid fever in the United States army and navy. Am J Public Health Nations Health. 1934 Jul;24(7):689–709.Google Scholar
  58. 58.
    Frawley JM. The treatment of typhoid fever in children by means of lysed vaccine. Cal West Med. 1938 Jun;48(6):415–17.Google Scholar
  59. 59.
    Siler JF, Dunham GC. Duration of immunity conferred by typhoid vaccine: results of re-vaccination by intracutaneous injection of typhoid vaccine. Am J Public Health Nations Health. 1939 Feb;29(2):95–103.Google Scholar
  60. 60.
    Raettig H. [Indication for vaccination against typhoid fever.]. Dtsch Med Wochenschr. 1954 Jan 29;79(5):173–4.Google Scholar
  61. 61.
    Warren JW, Hornick RB. Immunization against typhoid fever. Ann Rev Med. 1979;30:457–72.CrossRefPubMedGoogle Scholar
  62. 62.
    Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet. 1990 Oct 13;336(8720):891–4.Google Scholar
  63. 63.
    Simanjuntak CH, Paleologo FP, Punjabi NH, Darmowigoto R, Soeprawoto, Totosudirjo H et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet. 1991 Oct 26;338(8774):1055–9.Google Scholar
  64. 64.
    Engels EA, Lau J. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev. 2000;2:CD001261.PubMedGoogle Scholar
  65. 65.
    Fraser A, Paul M, Goldberg E, Acosta CJ, Leibovici L. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine. 2007 Nov 7;25(45):7848–57.Google Scholar
  66. 66.
    Wang JY, Noriega FR, Galen JE, Barry E, Levine MM. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909. Infect Immun. 2000 Aug;68(8):4647–52.Google Scholar
  67. 67.
    Tacket CO, Ferreccio C, Robbins JB, Tsai CM, Schulz D, Cadoz M et al. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis. 1986 Aug;154(2):342–5.Google Scholar
  68. 68.
    Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med. 1987 Oct 29;317(18):1101–4.Google Scholar
  69. 69.
    Klugman KP, Gilbertson IT, Koornhof HJ, Robbins JB, Schneerson R, Schulz D et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet. 1987 Nov 21;2(8569):1165–9.Google Scholar
  70. 70.
    Tacket CO, Levine MM, Robbins JB. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever. Vaccine. 1988 Aug;6(4):307–8.Google Scholar
  71. 71.
    Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine. 1996 Apr;14(5):435–8.Google Scholar
  72. 72.
    Arya SC. Efficacy of Salmonella typhi Vi capsular polysaccharide vaccine in South Africa. Vaccine. 1997 Feb;15(2):244.Google Scholar
  73. 73.
    Chen X, Stanton B, Pach A, Nyamete A, Ochiai RL, Kaljee L et al. Adults’ perceived prevalence of enteric fever predicts laboratory-validated incidence of typhoid fever in children. J Health Popul Nutr. 2007 Dec;25(4):469–78.Google Scholar
  74. 74.
    Kaljee LM, Pham V, Son ND, Hoa NT, Thiem VD, Canh do G et al. Trial participation and vaccine desirability for Vi polysaccharide typhoid fever vaccine in Hue City, Viet Nam. Trop Med Int Health. 2007 Jan;12(1):25–36.Google Scholar
  75. 75.
    Bodhidatta L, Taylor DN, Thisyakorn U, Echeverria P. Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine. Rev Infect Dis. 1987 Jul–Aug;9(4):841–5.Google Scholar
  76. 76.
    Yang HH Experience of school based vaccination in typhoid fever endemic area using Vi manufactured in China. Typhoid Fever, a Neglected Disease: Towards a Vaccine Introduction Policy, Annecy, 2–4 April 2007.Google Scholar
  77. 77.
    Acosta CJ, Galindo CM, Ochiai RL, Danovaro-Holliday MC, Page AL, Thiem VD et al. The role of epidemiology in the introduction of vi polysaccharide typhoid fever vaccines in Asia. J Health Popul Nutr. 2004 Sep;22(3):240–5.Google Scholar
  78. 78.
    Yang J, Acosta CJ, Si GA, Zeng J, Li CY, Liang DB et al. A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trial. BMC Publ Health. 2005 May;18(5):49.Google Scholar
  79. 79.
    Acosta CJ, Galindo CM, Ali M, Elyazeed RA, Ochiai RL, Danovaro-Holliday MC et al. A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: rationale and design. Trop Med Int Health. 2005 Dec;10(12):1219–28.Google Scholar
  80. 80.
    Agtini MD, Ochiai RL, Soeharno R, Lee HJ, Sundoro J, Hadinegoro SR et al. Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform. Publ Health. 2006 Nov;120(11):1081–7.Google Scholar
  81. 81.
    Khan MI, Ochiai RL, Hamza HB, Sahito SM, Habib MA, Soofi SB et al. Lessons and implications from a mass immunization campaign in squatter settlements of Karachi, Pakistan: an experience from a cluster-randomized double-blinded vaccine trial [NCT00125047]. Trials. 2006;7:17.Google Scholar
  82. 82.
    Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med. 2009 Jul 23;361(4):335–44.Google Scholar
  83. 83.
    Wahdan MH, Sérié C, Cerisier Y, Sallam S, Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis. 1982 Mar;145(3):292–5.Google Scholar
  84. 84.
    Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet. 1987 May 9;1(8541):1049–52.CrossRefPubMedGoogle Scholar
  85. 85.
    Black RE, Levine MM, Ferreccio C, Clements ML, Lanata C, Rooney J, Germanier R. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine. 1990 Feb;8(1):81–4.Google Scholar
  86. 86.
    Yang HH, Wu CG, Xie GZ, Gu QW, Wang BR, Wang LY, Wang HF, Ding ZS, Yang Y, Tan WS, Wang WY, Wang XC, Qin M, Wang JH, Tang HA, Jiang XM, Li YH, Wang ML, Zhang SL, Li GL. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ. 2001;79(7):625–31.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Zulfiqar A. Bhutta
    • 1
    Email author
  • M. Imran Khan
    • 1
  • Sajid Bashir Soofi
    • 1
  • R. Leon Ochiai
    • 1
  1. 1.Division of Women and Child HealthAga Khan UniversityKarachiPakistan

Personalised recommendations